A financial instrument that allows individuals to invest in a portfolio of personalized microbiome companies, gaining exposure to the burgeoning longevity market, while simultaneously donating a percentage of profits to research initiatives aimed at making gut health technology more accessible to underserved communities. This addresses the inequality that grows with access to expensive genetic engineering.